Affordable Access

deepdyve-link
Publisher Website

Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.

Authors
  • Font, Albert
  • Salazar, Ramon
  • Maurel, Joan
  • Taron, Miquel
  • Ramirez, Jose Luis
  • Tabernero, Josep
  • Gallego, Rosa
  • Casado, Esther
  • Manzano, Jose Luis
  • Carcereny, Enric
  • Guix, Marta
  • Fernández-Llamazares, Jaume
  • Rosell, Rafael
Type
Published Article
Journal
Cancer Chemotherapy and Pharmacology
Publisher
Springer-Verlag
Publication Date
Nov 01, 2008
Volume
62
Issue
6
Pages
1075–1083
Identifiers
DOI: 10.1007/s00280-008-0700-3
PMID: 18335219
Source
Medline
License
Unknown

Abstract

CPT-11/docetaxel plus cisplatin is active in patients with advanced esophagogastric cancer. XRCC3 Met241Thr polymorphisms could be a useful marker to predict prognosis in patients treated with a cisplatin-based chemotherapy. However, these results are required to be confirmed with a great number of patients.

Report this publication

Statistics

Seen <100 times